Tonix Pharmaceuticals Completed The Clinical Phase Of The Phase 2 UPLIFT1 Study Of TNX-601 ER As A Potential Treatment For Major Depressive Disorder. Topline Results From The Intention-to-treat Sample (N=132) Are Expected In Early November 2023
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has completed the clinical phase of the Phase 2 UPLIFT1 study of TNX-601 ER, a potential treatment for Major Depressive Disorder. The topline results from the intention-to-treat sample are expected in early November 2023.
October 16, 2023 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' completion of the clinical phase of the Phase 2 UPLIFT1 study could potentially impact the company's stock positively, as it brings them one step closer to potentially having a new treatment for Major Depressive Disorder.
The completion of the clinical phase of a study is a significant milestone in drug development. This news indicates progress in Tonix Pharmaceuticals' pipeline, which could positively impact investor sentiment and potentially the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100